Helus Pharma, operating as Cybin Inc., is a clinical-stage biotech focusing on deuterated serotonergic therapies for depression and anxiety. Its key asset, HLP003, is set to report Phase 3 trial results in Q4 2026, a milestone supported by recent fundraising and a debt-free balance sheet. Another asset, HLP004, shows potential for treating generalized anxiety disorder but is in earlier development stages. The company’s promising drug candidates offer growth potential despite typical biotech risks.
The global acetic acid market, valued at $18.57 billion in 2025, is projected to grow at a CAGR of 6.52% to reach $34.96 billion by 2035. Growth is driven primarily by rising demand for vinyl acetate monomer (VAM) used in adhesives, coatings, and pac...
Mavenir received Deutsche Telekom's Partner of the Year Award for Best Network Innovation, recognizing its role in the MeeC project that cut 5G core network energy use by up to 65%. The project uses AI-driven traffic analysis and workload optimizatio...
Mavenir was awarded Deutsche Telekom's Partner of the Year for its Most Energy Efficient Core (MeeC) project, which reduces 5G core network energy use by up to 65% during low traffic periods without compromising performance. The project, launched in ...
Mavenir received Deutsche Telekom's Partner of the Year award for network innovation, recognizing its key role in the MeeC project that reduced 5G core network energy consumption by up to 65% during low traffic periods. The MeeC initiative uses AI-dr...
Mavenir received Deutsche Telekom's Partner of the Year Award for Best Network Innovation due to its MeeC project, which achieved up to 65% energy savings in Deutsche Telekom's 5G core network without compromising performance. The MeeC initiative use...
